» Articles » PMID: 7812927

Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) Oncogene Are Frequent in Cervical and Vulvar Squamous Cell Carcinoma Cell Lines

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1995 Jan 15
PMID 7812927
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: CYCLIN D1, a cell-cycle control gene, recently has been shown to be identical to an oncogene alternatively known as BCL-1 and PRAD1 and implicated in centrocytic lymphomas and parathyroid adenomas, respectively. PRAD1 complexes to the product of the retinoblastoma (Rb) tumor suppressor gene, an event followed by Rb inactivation. Squamous cell carcinomas of the cervix and vulva are gynecologic tumors in which human papillomaviruses have been implicated as an initiating event, and proteins derived from these viruses also complex with an inactivate Rb. Because of the overlap in some of the molecular processes mediated by human papillomaviruses and by the PRAD1 oncogene, the authors analyzed the PRAD1 (CYCLIN D1/BCL-1) genomic structure and expression in vulvar and cervical squamous cell carcinoma cell lines.

Methods: PRAD1 DNA and PRAD1 mRNA expression were assessed by Southern and Northern blotting, respectively, in 13 squamous cell carcinoma cell lines of gynecologic origin (10, cervical cancer; 3, vulvar cancer).

Results: We found low baseline levels of a 4.5-kb PRAD1 transcript in a series of control cell lines, which were derived from normal fibroblasts, various hematologic malignancies, and a choriocarcinoma. PRAD1 mRNA overexpression (> or = 10-fold greater than that in control lines) was seen in all three vulvar carcinoma cell lines, two of which also showed amplification (5-fold and > 10-fold) of PRAD1 genomic sequences. Abnormalities of PRAD1 also were seen in 4 of the 10 cervical cancer cell lines and included overexpression of PRAD1 transcripts (3-9-fold) in 3 lines and rearrangement of PRAD1 DNA in an additional line that, however, did not shown any aberration in PRAD1 mRNA as discernible by Northern blotting. PRAD1 abnormalities were observed in three of the four cervical cell lines derived from metastatic sites and in one of the six cervical lines derived from primary tissue.

Conclusions: Seven of 13 squamous cell lines of gynecologic origin showed abnormalities of PRAD1. These abnormalities included amplification and rearrangement of DNA and overexpression of mRNA. The role of PRAD1 as a cell-cycle regulatory gene and its interactions with the Rb tumor suppressor gene suggests that PRAD1 deregulation may be a significant molecular event in the evolution of these tumors.

Citing Articles

A Brief Overview of Oncogenes and Signal Transduction Pathways in Gynecological Cancer.

Kontomanolis E, Koutras A, Fasoulakis Z, Syllaios A, Diakosavvas M, Angelou K Cancer Diagn Progn. 2022; 2(2):134-143.

PMID: 35399174 PMC: 8962808. DOI: 10.21873/cdp.10087.


Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature.

Maccio A, Donisi C, Sanna E, Chiappe G, Nemolato S, Melis L Diagnostics (Basel). 2021; 11(11).

PMID: 34829431 PMC: 8624694. DOI: 10.3390/diagnostics11112085.


EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.

Iida K, Nakayama K, Rahman M, Rahman M, Ishikawa M, Katagiri A Br J Cancer. 2011; 105(3):420-7.

PMID: 21730982 PMC: 3172895. DOI: 10.1038/bjc.2011.222.


Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population.

Satinder K, Chander S, Pushpinder K, Indu G, Veena J Mol Cell Biochem. 2008; 315(1-2):151-7.

PMID: 18548202 DOI: 10.1007/s11010-008-9799-0.


RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis.

Watts K, Cottrell E, Hoban P, Spiteri M Respir Res. 2006; 7:88.

PMID: 16776827 PMC: 1513217. DOI: 10.1186/1465-9921-7-88.